Results 191 to 200 of about 37,430 (216)

Lenalidomide

Reactions Weekly, 2022
openaire   +2 more sources

Lenalidomide

Reactions Weekly, 2015
openaire   +2 more sources

Lenalidomide

Reactions Weekly, 2019
  +4 more sources

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Annals of Oncology, 2011
Pier Luigi Zinzani, D Pietronigro, P L Zinzani   +2 more
exaly  

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy

Annals of Oncology, 2006
Toni K Choueiri, Jérôme Zeldis, Steven Andresen   +2 more
exaly  

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

Blood, 2011
Mark J. Smyth, David S Ritchie
exaly  

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Annals of Oncology, 2013
Pier Luigi Zinzani, P L Zinzani, J Polikoff   +2 more
exaly  

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

Annals of Oncology, 2017
Eric D. Hsi, N L Bartlett, S -H Jung
exaly  

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Blood, 2010
David H Vesole, Andrzej Jakubowiak, Jonathan L Kaufman   +2 more
exaly  

A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma

Annals of Oncology, 2014
E Pujade-Lauraine, L Favier, F Selle
exaly